Insmed's Stock Performance#
Insmed Incorporated (NASDAQ:INSM) saw its shares jump by 6.6% on Monday. This increase followed the announcement of positive results from the Phase 3b ENCORE study of its drug, ARIKAYCE.
Study Results Overview#
The ENCORE study successfully met its main goal, showing significant improvements in patients' respiratory symptoms and culture conversion rates. Specifically, patients receiving ARIKAYCE alongside standard multidrug therapy experienced a 3.11-point improvement in their respiratory symptom scores after 13 months compared to those receiving a placebo. The statistical measure used, known as the p-value, was 0.0299, indicating strong evidence that the results were not due to chance.
Comparison with Placebo#
The trial compared ARIKAYCE plus multidrug therapy to a placebo (a treatment with no active ingredients) plus the same multidrug therapy. By the sixth month, 87.8% of patients taking ARIKAYCE showed culture conversion, meaning the infection was no longer detectable, compared to just 57.0% in the placebo group. This reflects a significant difference of 30.8 percentage points. Additionally, by the 15-month mark, 76.2% of ARIKAYCE patients maintained this improvement, compared to 47.6% in the placebo group.
Safety Profile and Future Plans#
The safety profile of ARIKAYCE remained consistent with previous findings, with no new safety concerns reported. Common side effects included voice changes (58.7%), cough (32.9%), and fatigue (17.4%). The rate of patients discontinuing treatment was higher in the ARIKAYCE group at 18.3%, compared to 11.8% in the placebo group.
Looking ahead, Insmed plans to submit a supplemental new drug application to the FDA in the second half of 2026 to seek approval for broader use of ARIKAYCE. They also intend to share these findings with Japan's Pharmaceuticals and Medical Devices Agency during the same period. This study was conducted to meet regulatory requirements set by the FDA for ARIKAYCE.